379 related articles for article (PubMed ID: 10925331)
41. Safety evaluation of tirofiban.
Valgimigli M; Tebaldi M
Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
[TBL] [Abstract][Full Text] [Related]
42. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
[TBL] [Abstract][Full Text] [Related]
43. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
44. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
45. Platelet glycoprotein IIb/IIIa inhibitors.
Rosove MH
Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
[TBL] [Abstract][Full Text] [Related]
46. GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
Musumeci G; Baroni M; Rossini R
Curr Vasc Pharmacol; 2012 Jul; 10(4):443-7. PubMed ID: 22339252
[TBL] [Abstract][Full Text] [Related]
47. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
[No Abstract] [Full Text] [Related]
48. [GPIIb-IIIa inhibitors].
Nurden P
Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
[TBL] [Abstract][Full Text] [Related]
49. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice.
Tamhane UU; Gurm HS
Expert Opin Drug Saf; 2008 Nov; 7(6):809-19. PubMed ID: 18983227
[TBL] [Abstract][Full Text] [Related]
50. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Kleiman NS
Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
[TBL] [Abstract][Full Text] [Related]
51. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
Vakili BA; Kaplan RC; Slater JN; Sherman W; Ravi KL; Green SJ; Sanborn TA; Brown DL
Am J Cardiol; 2003 Apr; 91(8):946-50. PubMed ID: 12686333
[TBL] [Abstract][Full Text] [Related]
52. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
[TBL] [Abstract][Full Text] [Related]
53. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
[TBL] [Abstract][Full Text] [Related]
54. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
55. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
56. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
57. Utilization of GP IIb/IIIa inhibitors in peripheral percutaneous interventions: current applications and in-hospital outcomes at a tertiary referral center.
Shammas NW; Dippel EJ; Shammas GA; Kumar A; Jerin M; Kennedy L
J Invasive Cardiol; 2008 Jun; 20(6):266-9. PubMed ID: 18523317
[TBL] [Abstract][Full Text] [Related]
58. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR; Talley JD; Braden GA; Tcheng JE; Casterella PJ; Moliterno DJ; Navetta FI; Berger PB; Popma JJ; Dangas G; Gallo R; Sane DC; Saucedo JF; Jia G; Lincoff AM; Theroux P; Holmes DR; Teirstein PS; Kereiakes DJ
Circulation; 2001 May; 103(21):2572-8. PubMed ID: 11382726
[TBL] [Abstract][Full Text] [Related]
59. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
Coto H
J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
[TBL] [Abstract][Full Text] [Related]
60. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
